Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Amortization of Deferred Charges (2023 - 2025)

Historic Amortization of Deferred Charges for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$375000.0.

  • Compass Therapeutics' Amortization of Deferred Charges fell 3489.21% to -$375000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$747000.0, marking a year-over-year increase of 6593.71%. This contributed to the annual value of -$1.7 million for FY2024, which is 4882.21% up from last year.
  • As of Q3 2025, Compass Therapeutics' Amortization of Deferred Charges stood at -$375000.0, which was down 3489.21% from -$128000.0 recorded in Q2 2025.
  • Compass Therapeutics' Amortization of Deferred Charges' 5-year high stood at $26000.0 during Q1 2025, with a 5-year trough of -$1.0 million in Q2 2023.
  • Its 3-year average for Amortization of Deferred Charges is -$486727.3, with a median of -$376000.0 in 2024.
  • Data for Compass Therapeutics' Amortization of Deferred Charges shows a peak YoY increase of 10691.49% (in 2025) and a maximum YoY decrease of 3489.21% (in 2025) over the last 5 years.
  • Quarter analysis of 3 years shows Compass Therapeutics' Amortization of Deferred Charges stood at -$812000.0 in 2023, then soared by 66.75% to -$270000.0 in 2024, then crashed by 38.89% to -$375000.0 in 2025.
  • Its Amortization of Deferred Charges stands at -$375000.0 for Q3 2025, versus -$128000.0 for Q2 2025 and $26000.0 for Q1 2025.